These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Nevada
|
27-2767540
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
|
13125 Danielson Street, #110
Poway, California
|
92064
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
x
|
|
(Do not check if a smaller
reporting company)
|
|
Page
|
||
|
|
3 | |
|
Item 1.
|
Financial Statements:
|
3 |
|
Condensed Balance Sheets as of March 31, 2012 (unaudited) and September 30, 2011
|
3
|
|
|
Condensed Statements of Operations for the three and six months ended March 31, 2012
and 2011 (unaudited)
|
4
|
|
|
Condensed Statements of Cash Flows for the six months ended March 31, 2012
and 2011 (unaudited)
|
5
|
|
|
Notes to Interim Condensed Financial Statements (unaudited)
|
6
|
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
14
|
|
Item 3.
|
Quantitative and Qualitative Disclosures about Market Risk
|
18
|
|
Item 4.
|
Controls and Procedures
|
18
|
|
PART II. OTHER INFORMATION
|
19
|
|
|
Item 1.
|
Legal Proceedings
|
19
|
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
19
|
|
Item 3.
|
Defaults Upon Senior Securities
|
19
|
|
Item 4.
|
Mine Safety Disclosures
|
19
|
|
Item 5.
|
Other Information
|
19
|
|
Item 6.
|
Exhibits
|
19
|
|
SIGNATURES
|
20
|
|
|
March 31, 2012
|
September 30,
2011
|
|||||||
|
(unaudited)
|
||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash
|
$ | 7,181,744 | $ | 491,764 | ||||
|
Inventories, net
|
460,862 | 273,268 | ||||||
|
Prepaid expenses and other current assets
|
105,085 | 64,971 | ||||||
|
Total current assets
|
7,747,691 | 830,003 | ||||||
|
Equipment and tooling
, net
|
120,689 | 145,252 | ||||||
|
Intangible assets
, net
|
1,340,411 | 148,540 | ||||||
|
Total assets
|
$ | 9,208,791 | $ | 1,123,795 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 357,461 | $ | 164,190 | ||||
|
Accrued liabilities
|
65,375 | 14,750 | ||||||
|
Deferred officer compensation
|
- | 224,400 | ||||||
|
Due to related parties
|
375,000 | - | ||||||
|
Total current liabilities
|
797,836 | 403,340 | ||||||
|
Commitments and contingencies (Note 8)
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock, $0.001 par value, authorized
1,000,000 shares,
none issued and outstanding
|
- | - | ||||||
|
Common stock, $0.001 par value, authorized
50,000,000 shares,
6,223,761 and 3,903,762 shares
issued and outstanding, respectively
|
6,224 | 3,904 | ||||||
|
Additional paid-in capital
|
12,067,454 | 2,886,960 | ||||||
|
Accumulated deficit
|
(3,662,723 | ) | (2,170,409 | ) | ||||
|
Total stockholders' equity
|
8,410,955 | 720,455 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 9,208,791 | $ | 1,123,795 | ||||
|
Three Months Ended
March 31,
|
Six Months Ended
March 31,
|
|||||||||||||||
|
2012
|
2011
|
2012
|
2011
|
|||||||||||||
|
Revenues:
|
||||||||||||||||
|
Product sales
|
$ | 55,824 | $ | - | $ | 119,239 | $ | - | ||||||||
|
Other revenue
|
3,870 | - | 5,236 | - | ||||||||||||
|
Total revenues
|
59,694 | - | 124,475 | - | ||||||||||||
|
Cost of revenues
|
27,151 | - | 52,067 | - | ||||||||||||
|
Gross profit
|
32,543 | - | 72,408 | - | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
725,639 | 147,991 | 1,064,598 | 277,335 | ||||||||||||
|
Research and development
|
267,503 | 152,381 | 498,208 | 278,778 | ||||||||||||
|
Total operating expenses
|
993,142 | 300,372 | 1,562,806 | 556,113 | ||||||||||||
|
Loss from operations
|
(960,599 | ) | (300,372 | ) | (1,490,398 | ) | (556,113 | ) | ||||||||
|
Other income (expense):
|
||||||||||||||||
|
Interest and note discount amortization
|
- | (75,580 | ) | - | (145,856 | ) | ||||||||||
|
Other
|
(698 | ) | 639 | (1,916 | ) | 716 | ||||||||||
| (698 | ) | (74,941 | ) | (1,916 | ) | (145,140 | ) | |||||||||
|
Net loss
|
$ | (961,297 | ) | $ | (375,313 | ) | $ | (1,492,314 | ) | $ | (701,253 | ) | ||||
|
|
||||||||||||||||
|
Net loss per basic and diluted common share (1)
|
$ | (0.22 | ) | $ | (0.12 | ) | $ | (0.36 | ) | $ | (0.22 | ) | ||||
|
Weighted average common shares used to compute
net loss per basic and diluted common share (1)
|
4,385,981 | 3,225,657 | 4,147,881 | 3,142,531 | ||||||||||||
|
(1)
|
Net loss per share and weighted average common shares outstanding for all periods reflect the 1-for-5 reverse stock split that was effective March 21, 2012 (see Note 1).
|
|
Six Months Ended
March 31,
|
||||||||
|
2012
|
2011
|
|||||||
|
|
||||||||
|
Cash Flows From Operating Activities:
|
||||||||
|
Net loss
|
$ | (1,492,314 | ) | $ | (701,253 | ) | ||
|
Adjustments to reconcile net loss to net cash
used in operating activities:
|
||||||||
|
Depreciation and amortization
|
74,827 | 23,195 | ||||||
|
Debt discount and deferred financing cost amortization
|
- | 117,933 | ||||||
|
Warranty provision
|
5,053 | - | ||||||
|
Non-cash inventory reserve reduction
|
(8,201 | ) | - | |||||
|
Share-based compensation
|
559,851 | 90,315 | ||||||
|
Impairment of patents
|
- | 28,616 | ||||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses and other current assets
|
(40,114 | ) | (24,549 | ) | ||||
|
Inventories
|
(179,393 | ) | (5,952 | ) | ||||
|
Accounts payable
|
193,271 | (94,364 | ) | |||||
|
Accrued liabilities
|
50,501 | 2,923 | ||||||
|
Deferred officer compensation
|
(84,400 | ) | 112,200 | |||||
|
Due to related parties
|
125,000 | - | ||||||
|
Warranty settlements
|
(4,929 | ) | - | |||||
|
Net cash used in operating activities
|
(800,848 | ) | (450,936 | ) | ||||
|
Cash Flows From Investing Activities:
|
||||||||
|
Capital expenditures for equipment and tooling
|
(9,042 | ) | (16,436 | ) | ||||
|
Patent costs paid
|
(8,093 | ) | (7,124 | ) | ||||
|
Net cash used in investing activities
|
(17,135 | ) | (23,560 | ) | ||||
|
Cash Flows From Financing Activities:
|
||||||||
|
Proceeds from sale of common stock and warrants
|
8,500,000 | 1,000,000 | ||||||
|
Offering costs paid
|
(1,153,287 | ) | (43,554 | ) | ||||
|
Proceeds from exercise of stock options
|
161,250 | - | ||||||
|
Net cash provided by financing activities
|
7,507,963 | 956,446 | ||||||
|
Net increase in cash and cash equivalents
|
6,689,980 | 481,950 | ||||||
|
Cash and cash equivalents, beginning of period
|
491,764 | 439,385 | ||||||
|
Cash and cash equivalents, end of period
|
$ | 7,181,744 | $ | 921,335 | ||||
|
Supplemental Disclosure of Non-Cash Investing and Financing Information:
|
||||||||
|
Technology purchased from related party for common stock
and obligation to pay $250,000
|
$ | 1,225,000 | $ | - | ||||
|
Stock options issues as payment for tooling obligation
|
- | 20,000 | ||||||
|
Deferred officer compensation paid in common shares
|
140,000 | - | ||||||
|
Issuance of warrants to underwriter
|
563,420 | - | ||||||
|
March 31,
2012
|
September 30,
2011
|
|||||||
|
Finished goods
|
$ | 180,496 | $ | 44,648 | ||||
|
Work in process
|
7,389 | 23,960 | ||||||
|
Raw materials
|
384,140 | 324,025 | ||||||
| 572,025 | 392,633 | |||||||
|
Reserve for obsolescence
|
(111,163 | ) | (119,365 | ) | ||||
| $ | 460,862 | $ | 273,268 | |||||
|
March 31,
2012
|
September 30,
2011
|
|||||||
|
Equipment
|
$ | 155,212 | $ | 146,170 | ||||
|
Tooling
|
124,299 | 124,299 | ||||||
| 279,511 | 270,469 | |||||||
|
Accumulated deprcciation
|
(158,822 | ) | (125,217 | ) | ||||
| $ | 120,689 | $ | 145,252 | |||||
|
March 31,
2012
|
September 30,
2011
|
|||||||
|
Purchased technology
|
$ | 1,225,000 | $ | - | ||||
|
Patents
|
180,269 | 166,128 | ||||||
|
Defensive patents
|
176,816 | 154,952 | ||||||
|
Licenses and trademarks
|
6,617 | 34,529 | ||||||
| 1,588,702 | 355,609 | |||||||
|
Accumulated amortization
|
(248,291 | ) | (207,069 | ) | ||||
| $ | 1,340,411 | $ | 148,540 | |||||
|
Fiscal Years Ending September 30,
|
Estimated
Amortization
|
|||
|
2012 (6 months remaining)
|
$ | 61,810 | ||
|
2013
|
113,401 | |||
|
2014
|
105,536 | |||
|
2015
|
98,573 | |||
|
2016
|
93,083 | |||
|
Thereafter
|
868,008 | |||
|
March 31,
2012
|
September 30,
2011
|
|||||||
|
Payroll and related
|
$ | 63,526 | $ | 8,183 | ||||
|
Warranty reserve
|
1,658 | 1,534 | ||||||
|
Customer deposits and other
|
191 | 5,033 | ||||||
| $ | 65,375 | $ | 14,750 | |||||
|
Six Months Ended
March 31,
|
||||
|
2012
|
2011
|
|||
|
Volatility
|
90%
|
100%
|
||
|
Risk-free interest rate
|
1.00%
|
1.13%
|
||
|
Forfeiture rate
|
0.00%
|
0.00%
|
||
|
Dividend yield
|
0.00%
|
0.00%
|
||
|
Expected life in years
|
4.67
|
4.75
|
||
|
Weighted average fair value of options granted
|
$3.00
|
$1.20
|
||
|
Three Months Ended
March 31,
|
Six Months Ended
March 31,
|
|||||||||||||||
|
2012
|
2011
|
2012
|
2011
|
|||||||||||||
|
Selling, general and administrative
|
$ | 284,298 | $ | 23,605 | $ | 436,589 | $ | 43,199 | ||||||||
|
Research and development
|
79,251 | 27,735 | 123,262 | 47,116 | ||||||||||||
| $ | 363,549 | $ | 51,340 | $ | 559,851 | $ | 90,315 | |||||||||
|
Number
of Shares
|
Weighted Average
Exercise Price
|
Aggregate
Intrinsic Value (2)
|
||||||||||
|
Outstanding October 1, 2011
|
347,000 | $ | 1.80 |
|
||||||||
|
Granted
|
731,000 | $ | 3.54 |
|
||||||||
|
Canceled/expired
|
(112,500 | ) | $ | 4.20 |
|
|||||||
|
Exercised
|
(100,000 | ) | $ | 1.61 |
|
|||||||
|
Outstanding March 31, 2012 (1)
|
865,500 | $ | 3.05 | $ | 1,267,925 | |||||||
|
Exercisable March 31, 2012
|
300,469 | $ | 2.55 | $ | 591,461 | |||||||
|
(1)
|
Options outstanding are exercisable at prices ranging from $1.50 to $6.00 and expire in 2015 to 2017.
|
|
(2)
|
Aggregate intrinsic value is based on the closing price of our common stock on March 31, 2012 of $4.50.
|
|
Common Stock
|
Additional
Paid-In
|
Accumulated
|
Total
Stockholders'
|
|||||||||||||||||
|
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
||||||||||||||||
|
Balance at September 30, 2011
|
3,903,784 | $ | 3,904 | $ | 2,886,960 | $ | (2,170,409 | ) | $ | 720,455 | ||||||||||
|
Common shares issued upon exercise of
stock options by officers and directors
|
100,000 | 100 | 161,150 | - | 161,250 | |||||||||||||||
|
Common shares issued for assignment
of patents and intellectual property
from related party (Note 9)
|
300,000 | 300 | 974,700 | - | 975,000 | |||||||||||||||
|
Issuance of common shares at $4.50 per share
and underwriter warrants in secondary public
offering, net of issuance costs of $1,716,707
|
1,888,888 | 1,889 | 7,344,824 | - | 7,346,713 | |||||||||||||||
|
Common shares issued to officers for deferred
compensation
|
31,111 | 31 | 139,969 | - | 140,000 | |||||||||||||||
|
Share-based compensation expense
|
- | - | 559,851 | - | 559,851 | |||||||||||||||
|
Net loss for the period
|
- | - | - | (1,492,314 | ) | (1,492,314 | ) | |||||||||||||
|
Balance at March 31, 2012
|
6,223,783 | $ | 6,224 | $ | 12,067,454 | $ | (3,662,723 | ) | $ | 8,410,955 | ||||||||||
|
Number
|
Average Purchase
Price Per Share
|
|||||||
|
Shares purchasable under outstanding warrants at October 1, 2011
|
320,000 | $ | 3.75 | |||||
|
Stock purchase warrants issued
|
188,888 | $ | 5.625 | |||||
|
Stock purchase warrants exercised
|
- | |||||||
|
Shares purchasable under outstanding warrants at March 31, 2012
|
508,888 | $ | 4.45 | |||||
|
Description
|
Number of
Common Shares
|
Exercise Price
Per Share
|
Expiration Date
|
||||||
|
Stock Purchase Warrants (1)
|
320,000 | $ | 3.75 |
February 22, 2016
|
|||||
|
Stock Purchase Warrants
|
188,888 | $ | 5.625 |
March 21, 2017
|
|||||
|
(1)
|
Held by related parties.
|
|
|
·
|
market acceptance of our products and our ability to grow revenues;
|
|
|
·
|
the costs, timing and outcome of production [and regulatory compliance of our products;
|
|
|
·
|
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending any future intellectual property-related claims;
|
|
|
·
|
the costs and timing of additional product development and marketing efforts; and
|
|
|
·
|
the costs, timing and outcome of any future warranty claims or litigation against us associated with any of our products.
|
|
31.1
|
Certification of Kenneth F. Potashner, Principal Executive Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
Certification of James A. Barnes, Principal Financial Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Kenneth F. Potashner, Principal Executive Officer and James A. Barnes, Principal Financial Officer.
|
|
Extensible Business Reporting Language (XBRL) Exhibits*
|
|
|
101.INS
|
XBRL Instance Document*
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document*
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document*
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document*
|
|
101.LAB
|
XBRL Taxonomy Extension Labels Linkbase Document*
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document*
|
|
PARAMETRIC SOUND CORPORATION
|
||
|
Date: May 7, 2012
|
By:
|
/
S
/ JAMES A. BARNES
|
|
James A. Barnes, Chief Financial Officer, Treasurer and Secretary
|
||
|
(Principal Financial Officer)
|
||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|